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Web Appendix A: Details of 12 colon cancer trials.
Web Table 1: Data Summary of 12 colon cancer clinical trials
Study N Recurrences Recurrence Death Total Longest % in
Without Without Deaths Follow-Up Treatment
Death Recur (years) Group
1 247 116 14 13 115 9.9 49.0%
2 408 139 11 44 172 9.1 62.5%
3 926 377 31 76 422 11.4 49.4%
4 914 380 36 106 450 9.9 75.2%
5 878 297 33 74 338 12.6 49.8%
6 724 275 10 132 397 13.2 48.2%
7 683 206 32 129 303 12.9 50.1%
8 1040 356 36 67 387 9.7 49.8%
9 2077 605 57 176 724 9.4 66.7%
10 2128 574 66 192 700 10.3 49.8%
11 1549 394 71 115 438 8 50.3%
12 2409 627 189 106 544 6 49.8%
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Web Appendix B: Efficiency gains obtained through the proposed
method utilizing the multi-state cure model: model based esti-
mates.
Web Table 2: Kaplan-Meier treatment effect estimates (standard errors) and multi-state model
estimates (posterior standard deviations) for 10 colon cancer trials
∆S(5)∗ ∆DFS(3)∗∗
Full Follow-up Reduced Follow-up Full Follow-up Reduced Follow-up
Trial 1 Kaplan-Meier 0.090 (0.062) 0.098 (0.070) 0.122 (0.062) 0.132 (0.071)
Full Multi-State Model 0.105 (0.049) 0.107 (0.057) 0.150 (0.051) 0.141 (0.057)
Trial 2 Kaplan-Meier 0.057 (0.049) 0.039 (0.049) 0.056 (0.047) 0.076 (0.050)
Full Multi-State Model 0.051 (0.042) 0.053 (0.043) 0.068 (0.042) 0.070 (0.042)
Trial 4 Kaplan-Meier -0.023 (0.037) 0.027 (0.043) 0.004 (0.037) -0.003 (0.042)
Full Multi-State Model -0.024 (0.032) -0.010 (0.027) -0.015 (0.034) -0.003 (0.032)
Trial 5 Kaplan-Meier -0.023 (0.031) -0.009 (0.035) -0.015 (0.031) -0.026 (0.035)
Full Multi-State Model -0.032 (0.027) -0.029 (0.024) -0.017 (0.028) -0.018 (0.028)
Trial 6 Kaplan-Meier 0.037 (0.036) 0.026 (0.042) 0.048 (0.035) 0.031 (0.041)
Full Multi-State Model 0.009 (0.030) 0.004 (0.032) 0.033 (0.029) 0.032 (0.038)
Trial 7 Kaplan-Meier 0.080 (0.035) 0.122 (0.045) 0.037 (0.035) 0.082 (0.041)
Full Multi-State Model 0.039 (0.029) 0.051 (0.028) 0.040 (0.030) 0.043 (0.028)
Trial 8 Kaplan-Meier 0.105 (0.028) 0.112 (0.031) 0.084 (0.028) 0.116 (0.031)
Full Multi-State Model 0.095 (0.025) 0.085 (0.024) 0.103 (0.026) 0.096 (0.025)
Trial 10 Kaplan-Meier 0.004 (0.019) 0.012 (0.021) 0.007 (0.018) 0.018 (0.022)
Full Multi-State Model 0.012 (0.016) 0.015 (0.015) 0.010 (0.017) 0.008 (0.017)
Trial 11 Kaplan-Meier -0.0001 (0.021) 0.026 (0.030) -0.005 (0.021) -0.033 (0.026)
Full Multi-State Model 0.011 (0.018) 0.017 (0.017) -0.004 (0.019) -0.008 (0.019)
Trial 12 Kaplan-Meier 0.018 (0.017) 0.029 (0.019) 0.032 (0.017) 0.048 (0.020)
Full Multi-State Model 0.017 (0.015) 0.008 (0.013) 0.033 (0.017) 0.035 (0.016)
∗∆S(5) = P (T > 5|Zi = 1)− P (T > 5|Zi = 0)
∗∗∆DFS(3) = P (DFS > 3|Zi = 1)− P (DFS > 3|Zi = 0)
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Web Appendix C: Efficiency gains obtained through the proposed method uti-
lizing the multi-state cure model: imputation based estimates.
Web Table 3: Treatment effect on survival from original data, reduced follow-up data and
reduced follow-up data with imputation
Study Data Log-Rank Cox model 5 year
P-Value Log Hazard Ratio (SE) KM Estimate (SE)
1 Original 0.136 -0.28 (0.188) 0.090 (0.062)
Reduced follow-up 0.035 -0.45 (0.214) 0.098 (0.070)
Imputed Original 0.149 -0.31 (0.183) 0.092 (0.062)
Imputed Reduced follow-up 0.047 -0.39 (0.197) 0.104 (0.063)
Conlon, et al. (2011) method 0.117 -0.31 (0.199) 0.101 (0.065)
2 Original 0.097 -0.25 (0.155) 0.057 (0.049)
Reduced follow-up 0.255 -0.20 (0.179) 0.039 (0.049)
Imputed Original 0.105 -0.24 (0.154) 0.054 (0.048)
Imputed Reduced follow-up 0.187 -0.23 (0.176) 0.051 (0.049)
Conlon et al. (2011) method 0.203 -0.22 (0.175) 0.053 (0.050)
4 Original 0.719 0.06 (0.111) -0.023 (0.037)
Reduced follow-up 0.912 -0.005 (0.134) 0.027 (0.043)
Imputed Original 0.704 0.05 (0.109) -0.021 (0.037)
Imputed Reduced follow-up 0.843 0.003 (0.132) -0.005 (0.038)
Conlon et al. (2011) method 0.739 0.05 (0.131) -0.007 (0.038)
5 Original 0.355 0.09 (0.109) -0.023 (0.031)
Reduced follow-up 0.459 0.10 (0.134) -0.009 (0.035)
Imputed Original 0.464 0.06 (0.108) -0.021 (0.031)
Imputed Reduced follow-up 0.374 0.11 (0.129) -0.020 (0.032)
Conlon et al. (2011) method 0.443 0.09 (0.121) -0.019 (0.034)
6 Original 0.695 -0.04 (0.101) 0.037 (0.036)
Reduced follow-up 0.518 -0.08 (0.126) 0.026 (0.042)
Imputed Original 0.734 -0.04 (0.100) 0.037 (0.036)
Imputed Reduced follow-up 0.451 -0.09 (0.122) 0.024 (0.037)
Conlon et al. (2011) method 0.578 -0.06 (0.119) 0.019 (0.036)
7 Original 0.053 -0.20 (0.115) 0.080 (0.035)
Reduced follow-up 0.027 -0.33 (0.156) 0.122 (0.045)
Imputed Original 0.070 -0.21 (0.114) 0.077 (0.035)
Imputed Reduced follow-up 0.027 -0.31 (0.147) 0.079 (0.036)
Conlon et al. (2011) method 0.014 -0.35 (0.146) 0.081 (0.037)
8 Original 0.0004 -0.36 (0.103) 0.105 (0.028)
Reduced follow-up 0.0005 -0.41 (0.119) 0.112 (0.031)
Imputed Original 0.0004 -0.35 (0.102) 0.105 (0.028)
Imputed Reduced follow-up 0.0005 -0.40 (0.117) 0.103 (0.029)
Conlon et al. (2011) method 0.0004 -0.41 (0.116) 0.103 (0.030)
10 Original 0.827 -0.02 (0.076) 0.004 (0.019)
Reduced follow-up 0.398 -0.08 (0.092) 0.012 (0.021)
Imputed Original 0.788 -0.02 (0.076) 0.004 (0.018)
Imputed Reduced follow-up 0.502 -0.06 (0.091) 0.009 (0.019)
Conlonet al. (2011) method 0.505 -0.06 (0.088) 0.010 (0.019)
11 Original 0.907 0.007 (0.096) -0.0001 (0.021)
Reduced follow-up 0.456 -0.08 (0.118) 0.026 (0.030)
Imputed Original 0.930 0.02 (0.095) -0.002 (0.021)
Imputed Reduced follow-up 0.623 -0.05 (0.117) 0.005 (0.022)
Conlon et al. (2011) method 0.622 -0.05 (0.111) 0.007 (0.022)
12 Original 0.083 -0.14 (0.086) 0.018 (0.017)
Reduced follow-up 0.273 -0.09 (0.097) 0.029 (0.019)
Imputed Original 0.080 -0.14 (0.086) 0.018 (0.017)
Imputed Reduced follow-up 0.255 -0.09 (0.094) 0.019 (0.018)
Conlon et al. (2011) method 0.230 -0.10 (0.091) 0.018 (0.018)
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Web Appendix D: Simulation results under a misspecified model
Two additional simulations were performed to assess the robustness of the model and
proposed methods to model misspecification. Data for each simulation was generated as-
suming a multi-state cure model with a lognormal distribution for each of the four transition
times. Recurrence times and death times were simulated under this model to give “origi-
nal data” with long follow up. These times were then censored at an earlier time to give
“censored data”. The multi-state cure model with a Weibull baseline hazard function was
then fit to the data. Model based estimates of five year survival were then obtained from
the model fit to the “censored data” and the imputation strategy was performed on the
“censored data” to give the “imputed censored data”. Two trial settings were explored, one
with a treatment effect (Trial 1b) and one without a treatment effect (Trial 2b). For each
setting, we generate 500 data sets, each with 500 subjects per treatment arm, 750 subjects
with stage 3 disease, and a five year accrual period with eight years of additional follow-up
to provide the “original data”. The “censored data” is obtained by censoring these data sets
two years after the last accrual to provide a maximum of seven years of follow-up time. The




denotes treatment group and Si denotes stage. Each of these covariates are centered at 0
so that Zi is equal to -0.5 (0.5) for the control (treatment) group and Si is equal to -0.75
(0.25) for stage 2 (stage 3) disease. We set (γ0, γ1, γ2) = (−0.2, 0.5,−1.0) in trial 1b and
(γ0, γ1, γ2) = (−0.2, 0.0,−1.0) in trials 2b. For each transitions 1 → 4, 2 → 3 and 2 → 4,
we generate a time from a lognormal distribution with µkj = β0kj + βtrtkjZi + βstkjSi and
σkj, where µkj is the mean and σkj is the standard deviation of the log time for transi-
tion kj, respectively. For those who are cured of disease, we generate a death time with
σ14 = 2, β014 = 7 and the treatment and stage effects set to 0. For those who are not
cured we generate a recurrence time with (σ23, β023 , βtrt23 , βst23) = (1.5, 4.5, 0.7,−0.5) in trial
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1b and (σ23, β023 , βtrt23 , βst23) = (1.5, 4.5, 0,−0.5) in trial 2b. We generate a death time for
those who are not cured with σ24 = 2, β024 = 6 and the treatment and stage effects set to
0. If the death time for uncured subjects is less than the recurrence time, then a 2 → 4
transition is made at the death time and the recurrence is censored at the death time. If
the recurrence time is less than the death time, then a 2 → 3 transition is made at that
time. For those who recur, the time between their recurrence and death is generated with
(σ34, β034 , βtrt34 , βst34βTr) = (0.75, 5, 0,−0.3, 0.1). The results in Web Table 4 demonstrate
that smaller efficiency gains are obtained when the model is misspecified, but the Type I
error rate is still maintained.
Web Table 4: Simulation results using the multi-state cure model with Weibull baseline
hazards when data is generated from a lognormal distribution
Data Misspecified model, Treatment Effect, 2 year censored
Size of Cox model Log Hazard Ratio Coverage ∆S(5) ∆S(5) Coverage
Log-Rank Log Hazard Ratio (SD) S¯E Estimate (SD) S¯E
Original (max 13 year follow-up) 0.936 -0.23 (0.068) 0.068 0.062 (0.025) 0.025
7 year follow-up 0.940 -0.24 (0.070) 0.070 0.062 (0.025) 0.025
Censored (max 7 year follow-up) 0.958 -0.26 (0.071) 0.071 0.062 (0.028) 0.027
Censored, model based 0.063 (0.025) 0.025
Imputed Censored 0.956 -0.26 (0.072) 0.072 0.068 (0.026) 0.027
Misspecified model, No Treatment Effect, 2 year censored
Original (max 13 year follow-up) 0.042 0.004 (0.067) 0.068 0.96 -0.002 (0.025) 0.025 0.94
7 year follow-up 0.056 0.000 (0.072) 0.069 0.94 0.001 (0.025) 0.025 0.95
Censored (max 7 year follow-up) 0.052 0.002 (0.070) 0.072 0.95 -0.002 (0.027) 0.027 0.94
Censored, model based -0.001 (0.024) 0.025 0.95
Imputed Censored 0.054 0.002 (0.070) 0.072 0.95 -0.001 (0.025) 0.027 0.95
∆S(5) = P (T > 5 | Zi = 1)− P (T > 5 | Zi = 0)
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Web Appendix E: Efficiency gains obtained through the proposed
method utilizing the multi-state cure model with less informative
prior distributions
Sensitivity of the proposed methods to the prior distributions was explored for the two
trials considered. Imputation based estimates and model based estimates of overall survival
using Normal(0, 52) priors on the log(λ)’s, gamma priors with mean 1 and standard deviation
1.6 on the ρ’s, and Normal(0,22) on all of the covariate coefficients in the hazard models and
in the logistic model were obtained. There is some sensitivity to the priors in the point
estimates, but similar efficiency gains to those obtained under the more informative priors
are obtained for both the model based estimates and the imputation procedure.
Web Table 5: Model based and imputation based esti-
mates using the multi-state cure model with less informative priors for two colon cancer trials
Model based estimates Imputation based estimated
∆S(5)∗ ∆DFS(3)∗∗ Log-Rank Cox model 5 year
P-Value Log Hazard Ratio (SE) KM Estimate (SE)
Trial 3 Full Follow-up 0.074 (0.031) 0.110 (0.031) 0.002 -0.31 (0.098) 0.074 (0.031)
Reduced Follow-up 0.115 (0.080) 0.210 (0.086) 0.045 -0.27 (0.131) 0.115 (0.080)
Multi-state Model Using
Reduced Follow-up Data 0.096 (0.033) 0.128 (0.032) 0.011 -0.30 (0.119) 0.080 (0.032)
Trial 9 Full Follow-up 0.034 (0.021) 0.032 (0.021) 0.041 -0.16 (0.077) 0.034 (0.021)
Reduced Follow-up 0.050 (0.026) 0.042 (0.022) 0.105 -0.14 (0.087) 0.050 (0.026)
Multi-state Model Using
Reduced Follow-up Data 0.042 (0.023) 0.049 (0.022) 0.082 -0.15 (0.086) 0.035 (0.021)
∗∆S(5) = P (T > 5|Zi = 1)− P (T > 5|Zi = 0)
∗∗∆DFS(3) = P (DFS > 3|Zi = 1)− P (DFS > 3|Zi = 0)
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Web Appendix F: Efficiency gains obtained through the proposed method uti-
lizing the multi-state cure model with restrictions on the treatment coefficients.
Li, et al. (2011) showed that when an intermediate variable captures even just a mod-
est amount of the treatment effect on the final outcome, efficiency gains of the estimated
treatment effect on the final outcome can be achieved by shrinking the treatment effect es-
timate in the conditional distribution of the final outcome given the intermediate variable
and treatment toward 0. In our setting, it is plausible that much of the treatment effect is
captured in the recurrence event by affecting the probability of being cured of disease and
the time to recurrence. Therefore, one strategy to potentially improve efficiency gains in the
estimation of the treatment effect on overall survival is to fit the multi-state cure model with
strong prior assumptions placed on the treatment effects of some transition times. Specifi-
cally, the treatment effect on time to death for those who are cured (1→ 4 transition) and
the treatment effect on time to death for those who are not cured but without recurrence
(2 → 4 transition) are likely close to zero as the treatment may affect the probability of
being cured, but after this most likely has little or no effect on the hazard of death from
other causes if the person does not die from cancer. The treatment effect on time to death
after recurrence (3→ 4 transition) is also likely near zero, as patients often go off treatment
or start new treatment regimens after a recurrence. We apply these restricted models to
the 12 colon cancer trials, one model with the above mentioned treatment effects shrunk
towards zero with the use of tighter prior distributions and another restricted model with
these treatment effects forced to be zero. The results of applying the imputation procedure
to these models are shown in Web Table 6. Small additional efficiency gains were obtained
for some trials using these restricted models.
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Web Table 6: Treatment effect on survival from original data, reduced follow-up data and
reduced follow-up data with imputation and restrictions on treatment coefficients
Study Data Log-Rank Cox model 5 year
P-Value Log Hazard Ratio (SE) KM Estimate (SE)
1 Original 0.136 -0.28 (0.188) 0.090 (0.062)
Reduced follow-up 0.035 -0.45 (0.214) 0.098 (0.070)
Imputed Reduced follow-up, β14, β24, β34 shrunk to 0 0.045 -0.39 (0.197) 0.105 (0.063)
Imputed Reduced follow-up, β14 = β24 = β34 = 0 0.040 -0.40 (0.197) 0.105 (0.063)
2 Original 0.097 -0.25 (0.155) 0.057 (0.049)
Reduced follow-up 0.255 -0.20 (0.179) 0.039 (0.049)
Imputed Reduced follow-up, β14, β24, β34 shrunk to 0 0.199 -0.23 (0.177) 0.051 (0.049)
Imputed Reduced follow-up, β14 = β24 = β34 = 0 0.179 -0.24 (0.176) 0.051 (0.049)
3 Original 0.002 -0.31 (0.098) 0.074 (0.031)
Reduced follow-up 0.045 -0.27 (0.131) 0.115 (0.080)
Imputed Reduced follow-up, β14, β24, β34 shrunk to 0 0.010 -0.31 (0.118) 0.082 (0.033)
Imputed Reduced follow-up, β14 = β24 = β34 = 0 0.005 -0.33 (0.117) 0.092 (0.033)
4 Original 0.719 0.06 (0.111) -0.023 (0.037)
Reduced follow-up 0.912 -0.005 (0.134) 0.027 (0.043)
Imputed Reduced follow-up, β14, β24, β34 shrunk to 0 0.832 0.02 (0.130) -0.006 (0.038)
Imputed Reduced follow-up, β14 = β24 = β34 = 0 0.841 0.01 (0.131) -0.004 (0.038)
5 Original 0.355 0.09 (0.109) -0.023 (0.031)
Reduced follow-up 0.459 0.10 (0.134) -0.009 (0.035)
Imputed Reduced follow-up, β14, β24, β34 shrunk to 0 0.405 0.10 (0.125) -0.019 (0.032)
Imputed Reduced follow-up, β14 = β24 = β34 = 0 0.459 0.09 (0.124) -0.017 (0.032)
6 Original 0.695 -0.04 (0.101) 0.037 (0.036)
Reduced follow-up 0.518 -0.08 (0.126) 0.026 (0.042)
Imputed Reduced follow-up, β14, β24, β34 shrunk to 0 0.384 -0.11 (0.121) 0.026 (0.038)
Imputed Reduced follow-up, β14 = β24 = β34 = 0 0.387 -0.10 (0.119) 0.026 (0.037)
7 Original 0.053 -0.20 (0.115) 0.080 (0.035)
Reduced follow-up 0.027 -0.33 (0.156) 0.122 (0.045)
Imputed Reduced follow-up, β14, β24, β34 shrunk to 0 0.026 -0.31 (0.144) 0.078 (0.036)
Imputed Reduced follow-up, β14 = β24 = β34 = 0 0.037 -0.28 (0.142) 0.074 (0.036)
8 Original 0.0004 -0.36 (0.103) 0.105 (0.028)
Reduced follow-up 0.0005 -0.41 (0.119) 0.112 (0.031)
Imputed Reduced follow-up, β14, β24, β34 shrunk to 0 0.0005 -0.40 (0.115) 0.104 (0.029)
Imputed Reduced follow-up, β14 = β24 = β34 = 0 0.0005 -0.40 (0.115) 0.103 (0.029)
9 Original 0.041 -0.16 (0.077) 0.034 (0.021)
Reduced follow-up 0.105 -0.14 (0.087) 0.050 (0.026)
Imputed Reduced follow-up, β14 = β24 = β34 = 0 0.071 -0.15 (0.085) 0.035 (0.021)
Imputed Reduced follow-up, hierarchical model 0.082 -0.15 (0.086) 0.035 (0.021)
10 Original 0.827 -0.02 (0.076) 0.004 (0.019)
Reduced follow-up 0.398 -0.08 (0.092) 0.012 (0.021)
Imputed Reduced follow-up, β14, β24, β34 shrunk to 0 0.511 -0.06 (0.089) 0.008 (0.019)
Imputed Reduced follow-up, β14 = β24 = β34 = 0 0.585 -0.05 (0.088) 0.007 (0.019)
11 Original 0.907 0.007 (0.096) -0.0001 (0.021)
Reduced follow-up 0.456 -0.08 (0.118) 0.026 (0.030)
Imputed Reduced follow-up, β14, β24, β34 shrunk to 0 0.758 -0.01 (0.114) 0.003 (0.022)
Imputed Reduced follow-up, β14 = β24 = β34 = 0 0.812 0.008 (0.113) -0.0002 (0.022)
12 Original 0.083 -0.14 (0.086) 0.018 (0.017)
Reduced follow-up 0.273 -0.09 (0.097) 0.029 (0.019)
Imputed Reduced follow-up, β14, β24, β34 shrunk to 0 0.194 -0.12 (0.092) 0.020 (0.018)
Imputed Reduced follow-up, β14 = β24 = β34 = 0 0.140 -0.12 (0.091) 0.023 (0.018)
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Web Appendix G: Efficiency gains obtained through the proposed method and
a hierarchical model.
Another way to extend the use of the multi-state model and potentially improve upon
the efficiency gains is to borrow information across trials by use of a hierarchical model.
The original multi-state models fit to each individual trial provide evidence for common
effects of some covariates on the probability of cure and transition rates. In particular, the
coefficients associated with age and stage in all of the sub-models were quite similar. In
addition, the coefficients associated with Tr in the 3 → 4 transition and the shape param-
eters of the Weibull models were similar across trials. We can therefore use a hierarchical
model to borrow information across trials and shrink selected parameters towards common
values. To illustrate this, we let ρskj ∼ N(ρkj, σ2ρkj)I(ρskj ≥ 0), βSTskj ∼ N(βSTkj, σ2βST kj),
βAGEskj ∼ N(βAGEkj, σ2βAGEkj), βTrs34 ∼ N(βTr34, σ2βTr34), γSTskj ∼ N(γSTkj, σ2γST kj), and
γAGEskj ∼ N(γAGEkj, σ2γAGEkj), where kj = {12, 23, 24, 34} corresponds to the transition and
s = 1, ..., 12 represents the study number. We place Gamma hyper-priors with mean 1 and
standard deviation 1 on ρkj and on σρkj, σβST kj, σβAGEkj, σβTrkj, σγST kj, and σγAGEkj and
N(0, 22) hyper-priors on βAGEkj, βSTkj, βTrkj, γSTkj, and γAGEkj. The remaining parameters
are independent across studies. For the reduced follow-up data, we fit the hierarchical model
separately 12 times, each time with 1 trial artificially censored and the remaining 11 with
their full follow-up data. The parameter estimates obtained from the hierarchical models can
then be used in estimating five year OS and three year DFS. Web Table 7 provides log-rank
p-values, Cox model log hazard ratio estimates and standard errors and Kaplan-Meier 5
year survival estimates and standard errors obtained from fitting the hierarchical model and
applying the imputation procedure. There are not, in general, additional efficiency gains,
likely due to the fact that these are all randomized trials and thus estimates for age and
stage are likely to be at most weakly correlated with the estimate for treatment.
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Web Table 7: Treatment effect on survival from original data, reduced follow-up data and
reduced follow-up data with imputation from a hierarchical model
Study Data Log-Rank Cox model 5 year
P-Value Log Hazard Ratio (SE) KM Estimate (SE)
1 Original 0.136 -0.28 (0.188) 0.090 (0.062)
Reduced follow-up 0.035 -0.45 (0.214) 0.098 (0.070)
Imputed Reduced follow-up, hierarchical model 0.057 -0.38 (0.203) 0.102 (0.063)
2 Original 0.097 -0.25 (0.155) 0.057 (0.049)
Reduced follow-up 0.255 -0.20 (0.179) 0.039 (0.049)
Imputed Reduced follow-up, hierarchical model 0.215 -0.22 (0.178) 0.048 (0.049)
3 Original 0.002 -0.31 (0.098) 0.074 (0.031)
Reduced follow-up 0.045 -0.27 (0.131) 0.115 (0.080)
Imputed Reduced follow-up, hierarchical model 0.027 -0.27 (0.122) 0.072 (0.033)
4 Original 0.719 0.06 (0.111) -0.023 (0.037)
Reduced follow-up 0.912 -0.005 (0.134) 0.027 (0.043)
Imputed Reduced follow-up, hierarchical model 0.823 0.01 (0.132) -0.002 (0.038)
5 Original 0.355 0.09 (0.109) -0.023 (0.031)
Reduced follow-up 0.459 0.10 (0.134) -0.009 (0.035)
Imputed Reduced follow-up, hierarchical model 0.385 0.11 (0.128) -0.019 (0.032)
6 Original 0.695 -0.04 (0.101) 0.037 (0.036)
Reduced follow-up 0.518 -0.08 (0.126) 0.026 (0.042)
Imputed Reduced follow-up, hierarchical model 0.465 -0.09 (0.123) 0.023 (0.038)
7 Original 0.053 -0.20 (0.115) 0.080 (0.035)
Reduced follow-up 0.027 -0.33 (0.156) 0.122 (0.045)
Imputed Reduced follow-up, hierarchical model 0.026 -0.31 (0.147) 0.077 (0.036)
8 Original 0.0004 -0.36 (0.103) 0.105 (0.028)
Reduced follow-up 0.0005 -0.41 (0.119) 0.112 (0.031)
Imputed Reduced follow-up, hierarchical model 0.0005 -0.40 (0.117) 0.103 (0.029)
9 Original 0.041 -0.16 (0.077) 0.034 (0.021)
Reduced follow-up 0.105 -0.14 (0.087) 0.050 (0.026)
Imputed Reduced follow-up, hierarchical model 0.082 -0.15 (0.086) 0.035 (0.021)
10 Original 0.827 -0.02 (0.076) 0.004 (0.019)
Reduced follow-up 0.398 -0.08 (0.092) 0.012 (0.021)
Imputed Reduced follow-up, hierarchical model 0.488 -0.07 (0.091) 0.009 (0.019)
11 Original 0.907 0.007 (0.096) -0.0001 (0.021)
Reduced follow-up 0.456 -0.08 (0.118) 0.026 (0.030)
Imputed Reduced follow-up, hierarchical model 0.672 -0.03 (0.116) 0.007 (0.022)
12 Original 0.083 -0.14 (0.086) 0.018 (0.017)
Reduced follow-up 0.273 -0.09 (0.097) 0.029 (0.019)
Imputed Reduced follow-up, hierarchical model 0.226 -0.11 (0.095) 0.019 (0.017)
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